RESUMO
·AIM:To analyze the effect of Conbercept for exudative age-related macular degeneration ( ARMD) .·METHODS: There were 21 eye of 21 patients with exudative ARMD from January 2016 to January 2017 included. All the patients were treated with intravitreal injection of conbercept 0. 5mL (0. 5mg) and followed up for 3mo. The best corrected visual acuity ( BCVA) and central macular thickness (CMT) before and 1wk, 1 and 3mo after treatment were observed.·RESULTS:The BCVA and CMT before and 1wk, 1 and 3mo after treatment were 0. 9±1. 4, 0. 7±1. 2, 0. 5±1. 1 and 0. 4±0. 9. BCVA after treatment were different at different time (F=49. 12, P<0. 001); BCVA at 1wk and 1mo after treatment were not different compared with before treatment ( P> 0. 05 ); that at 3mo were significantly different compared with before (P<0. 05). There were 19 eyes with improved BCVA at 3mo after treatment, unchanged in 2 eyes. CMT before and at 1wk, 1 and 3mo were 404. 25±68. 76, 354. 25±43. 12, 271. 75±32. 30, 218. 30± 24. 70μm. CMT at different time were significantly different (F=2487. 45, P<0. 001);CMT at 1wk, 1 and 3mo were different compared with before treatment ( P <0. 001). There were no severe complications found.·CONCLUSION: Intravitreal injection of conbercept for exudative ARMD is remarkable.
RESUMO
AIM: To observe clinical efficacy of the intravitreal injection of conbercept treatment for exudative age -related macular degeneration. METHODS:Prospective study. Totally 112 senile patients (112 eyes) with exudative macular degeneration were randomly divided into study group and the control group, 56 cases in each group. The study group were treated with intravitreal injection of conbercept. The control group received conservative treatment. Uncorrected visual acuity and foveal retinal thickness were observed before and after treatment in the two groups. RESULTS: Visual acuity of study group improved significantly, and the most obvious improvement was observed at 6mo after treatment. Foveal retinal thickness of study group was reduced after treatment, and the most obvious decrease was observed at 6mo after treatment.CONCLUSION: Intravitreal injection of conbercept can improve visual acuity reduced foveal thickness in senile patients with exudative age - related macular degeneration.
RESUMO
Photodynamic therapy ( PDT ) is a new technique to diagnose and treat diseases with photodynamic effect produced by photosensitizer and light, and is now a main method of treating exudative age - related macular degeneration ( AMD ) . ln recent years, with the development of science and technology, combinations of PDT have become a research hot spot. ln this paper, we reviewed the research status of treatments on exudative AMD with PDT combined anti-VEGF drugs.